Skip to main content
Legend Biotech Corp logo

Legend Biotech Corp — Investor Relations & Filings

Ticker · LEGN ISIN · US52490G1022 LEI · 254900EIUFZTW136H859 US Manufacturing
Open in API
Filings indexed 343 across all filing types
Latest filing 2026-06-02 Regulatory Filings
Country KY Cayman Islands
Listing US LEGN

About Legend Biotech Corp

https://investors.legendbiotech.com/

Legend Biotech Corp. is a global, commercial-stage biotechnology company that discovers, develops, manufactures, and commercializes novel cell therapies. The company's primary focus is on treating life-threatening diseases, with a significant emphasis on oncology. Its lead product is CARVYKTI® (ciltacabtagene autoleucel), a chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of relapsed or refractory multiple myeloma. This therapy is developed and commercialized in collaboration with Johnson & Johnson. Legend Biotech is building an end-to-end cell therapy platform to maximize patient access to its treatments and to advance its pipeline of cutting-edge cell therapy modalities for various diseases.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 85% confidence The document is a Form 6-K (report of a foreign private issuer) furnishing a press release and conference abstract. It does not contain financial statements, voting results, management changes, or other specific items. It is a general regulatory announcement submitted on Form 6-K, fitting the fallback category for miscellaneous regulatory filings.
2026-06-02 English
FORM 6-K
Regulatory Filings Classification · 92% confidence The document is a Form 6-K filed by Legend Biotech (a SEC regulatory filing for a foreign private issuer), which attaches a press release and furnishes material under Exchange Act Rule 13a-16/15d-16. This is neither an earnings release nor an investor presentation but a general compliance submission with an attached press release. There is no substantive financial report or actual data in the text itself beyond the press announcement, so it falls under the general Regulatory Filings category (RNS).
2026-06-01 English
FORM 6-K
Regulatory Filings Classification · 91% confidence The document is a Form 6-K filing by a foreign private issuer, providing a press release as Exhibit 99.1 to satisfy SEC disclosure requirements under Rule 13a-16/15d-16. It does not itself contain financial statements, earnings data, or detailed report content, but rather furnishes a press release. This aligns with general regulatory announcements and does not fit a specific category like earnings release or investor presentation. Therefore, it is classified as a general Regulatory Filing (RNS).
2026-05-21 English
6-K - Legend Biotech Corp (0001801198) (Filer)
Interim / Quarterly Report Classification · 90% confidence The document is a Form 6-K filed by a foreign private issuer providing its unaudited interim condensed consolidated financial statements and Management’s Discussion and Analysis for the three months ended March 31, 2026. It contains full quarterly financial statements and MD&A rather than merely announcing or certifying a report, matching the definition of an Interim/Quarterly Report. Q1 2026
2026-05-12 English
6-K - Legend Biotech Corp (0001801198) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 6-K filed with the SEC by Legend Biotech Corporation, dated April 14, 2026. It announces preliminary sales figures for CARVYKTI for the quarter ended March 31, 2026. The document explicitly states that the sales data is preliminary, unaudited, and based on information from a partner (Janssen). It includes forward-looking statements and references the company's Annual Report on Form 20-F filed earlier. The document does not contain full financial statements or detailed financial analysis but serves as an update on sales performance for a recent quarter. Form 6-K filings are typically used by foreign private issuers to report material information between annual reports. Given the nature of the content—preliminary sales announcement for a quarter—and the absence of comprehensive financial statements or management discussion, this filing best fits the category of an Earnings Release (ER), which is the initial announcement of quarterly/periodical financial results (key highlights only). The document length (5554 characters) supports it being more than a brief announcement but not a full interim report. Therefore, the classification is ER with high confidence.
2026-04-14 English
4 - Legend Biotech Corp (0001801198) (Issuer)
Director's Dealing
2026-03-27 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.